1Lund SS, Vaag AA. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al[J]. Diabetes Care, 2009, 32(7):e90-91,author reply e92-93. 被引量：1
2Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled t riats[J]. Lancet, 2009,373 ( 9677): 1765-1772. 被引量：1
3Turnbull FM, Abraira C, Anderson R J, et al. Intensive glucose control and macrovascularouteomes in type 2 diabetes [J]. Diabetologia, 2009,52 ( 11 ) : 2288-2298. 被引量：1
4Zoungas S,de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial[J]. Diabetes Care, 2009,32 ( 11 ) : 2068-2074. 被引量：1
5International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes[J]. Diabetes Care,2009,32(7):1327-1334. 被引量：1
6American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care, 2010,33 ( Suppl 1 ) : S62- 67. 被引量：1
7American Diabetes Association. Standards of medical care in diabetes--2010[J]. Diabetes Care,2010033(Suppl 1) :S11-61. 被引量：1
8Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a muhicentre, randomised,open-label trial[J]. Lancet, 2009,373 (9681):2125-2135. 被引量：1
9Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. N Engl J Med,2007,356 (24):2457-2471. 被引量：1
1NISSEN SE, WOLSKI K. Effect of rosiglitazone on the risk of myocardial infarclion and death from cardiovascular causes [ J]. N Engl J Med,2007,356(24) :2457 -2471. 被引量：1
2HOME PD,POCOCK SJ,BECK-NIELSEN H ,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD) : a muhicentre, randomised, open-label trial [J]. Lancet,2009,373(9681 ) :2125 -2135. 被引量：1
3BARI 2D STUDY GROUP, FRYE RL,AUGUST P,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease [J]. N Engl J Med, 2009, 360 ( 24 ) :2503 - 2515. 被引量：1
6Zimmer PZ. The pathogenesis and prevention of diabetes in adults. Diabetes Care 1995 ;18(8) :1050. 被引量：1
7Expert Panel on Detection, Evaluation, and Treatent of High Blood Cholesterol in Adults. Excutive Summary of the Third Report of the National Cholesterol Education program(NCEP) Expert Paneel on Detection ,Evaluation, and treatment of High Blood Cholesterol in Adults( Adults Treatment panel Ⅲ). JAMA 2001 ;285 ( 19 ) :2486 - 2497. 被引量：1
8American Diabetes Association and National Institute of Diabetes , Diges tive and Kidney Diseases. The Prevention or Delay of Type 2 Diabetes. Diabetes Care 2002 ;25:742 -749. 被引量：1
9Riddle MC,Rosenstock J. The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003,(11):3080-3086. 被引量：1
10Janka HU,Apalewe G,Riddle MC. Comparson of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes[J].Diabetes Care,2005,(02):254-259. 被引量：1
